Unnamed: 0,title,date,stock,sentiment
1081794.0,"Stifel Maintains Buy on Repligen, Raises Price Target to $150",2020-05-27 08:10:00-04:00,RGEN,neutral
1081795.0,Regeneron Pharmaceuticals shares are trading lower after Sanofi said it would sell its investment in the company.,2020-05-26 13:59:00-04:00,RGEN,neutral
1081796.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,RGEN,positive
1081797.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,RGEN,neutral
1081798.0,Stocks That Hit 52-Week Highs On Friday,2020-05-15 10:33:00-04:00,RGEN,neutral
1081799.0,"The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO",2020-05-15 07:49:00-04:00,RGEN,negative
1081800.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,RGEN,neutral
1081801.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,RGEN,negative
1081802.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,RGEN,neutral
1081803.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-07 10:33:00-04:00,RGEN,neutral
1081804.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,RGEN,negative
1081805.0,"HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $143",2020-05-07 07:25:00-04:00,RGEN,neutral
1081806.0,"SVB Leerink Maintains Outperform on Repligen, Raises Price Target of $150",2020-05-07 06:23:00-04:00,RGEN,neutral
1081807.0,Why Repligen's Stocks Is Trading Higher Today,2020-05-06 11:48:00-04:00,RGEN,neutral
1081808.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-06 10:43:00-04:00,RGEN,neutral
1081809.0,Repligen shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-06 08:51:00-04:00,RGEN,positive
1081810.0,"Repligen Reaffirms FY20 Sales Guidance $309M-$319M, Raises Adj. EPS Guidance From $1.07-$1.12 To $1.09-$1.14",2020-05-06 07:36:00-04:00,RGEN,neutral
1081811.0,"Repligen Q1 Adj. EPS $0.320 Beats $0.210 Estimate, Sales $76.100M Beat $71.190M Estimate",2020-05-06 07:35:00-04:00,RGEN,neutral
1081812.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,RGEN,neutral
1081813.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,RGEN,neutral
1081814.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,RGEN,positive
1081815.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,RGEN,neutral
1081816.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,RGEN,negative
1081817.0,"Stifel Maintains Buy on Repligen, Lowers Price Target to $113",2020-04-02 11:33:00-04:00,RGEN,negative
1081818.0,"HC Wainwright & Co. Maintains Buy on Repligen, Lowers Price Target to $100",2020-03-23 10:47:00-04:00,RGEN,negative
1081819.0,"Stifel Nicolaus Maintains Buy on Repligen, Raises Price Target to $116",2020-02-21 09:07:00-05:00,RGEN,neutral
1081820.0,"Stephens & Co. Maintains Overweight on Repligen, Raises Price Target to $114",2020-02-21 07:22:00-05:00,RGEN,negative
1081821.0,"Repligen Sees FY20 Sales $309M-$319M Vs. 314.74M Est., EPS $1.07-$1.12 Vs. $1.10 Est.",2020-02-20 07:40:00-05:00,RGEN,neutral
1081822.0,"Repligen Q4 EPS $0.2 Beats $0.18 Estimate, Sales $69.5M Beat $68.37M Estimate",2020-02-20 07:38:00-05:00,RGEN,neutral
1081823.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,RGEN,negative
1081824.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,RGEN,neutral
1081825.0,24 Stocks Moving in Wednesday's Pre-Market Session,2020-02-19 07:29:00-05:00,RGEN,neutral
1081826.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,RGEN,positive
1081827.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,RGEN,negative
1081828.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,RGEN,neutral
1081829.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,RGEN,negative
1081830.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,RGEN,neutral
1081831.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,RGEN,neutral
1081832.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,RGEN,neutral
1081833.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,RGEN,negative
1081834.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,RGEN,neutral
1081835.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,RGEN,positive
1081836.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,RGEN,neutral
1081837.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,RGEN,neutral
1081838.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,RGEN,neutral
1081839.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,RGEN,neutral
1081840.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,RGEN,negative
1081841.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,RGEN,positive
1081842.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,RGEN,negative
1081843.0,"Benzinga's Top Upgrades, Downgrades For November 15, 2019",2019-11-15 09:59:00-05:00,RGEN,positive
1081844.0,"Stifel Nicolaus Initiates Coverage On Repligen with Buy Rating, Announces $105 Price Target",2019-11-15 06:50:00-05:00,RGEN,neutral
1081845.0,"Benzinga's Top Upgrades, Downgrades For Npvember 1, 2019",2019-11-01 09:45:00-04:00,RGEN,positive
1081846.0,First Analysis Upgrades Repligen to Strong Buy,2019-11-01 08:56:00-04:00,RGEN,positive
1081847.0,"The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut",2019-10-31 08:08:00-04:00,RGEN,positive
1081848.0,"Repligen Raises FY19 Sales Guidance From $264M-$268M To $267M-$270M vs $266M Estimate, Adj. EPS From $0.94-$0.98 To $1-$1.04 vs $0.97 Est.",2019-10-31 07:56:00-04:00,RGEN,neutral
1081849.0,"Repligen Q3 Adj. EPS $0.26 Up From $0.2 YoY, Sales $69.4M Up From $49.529M YoY",2019-10-31 07:55:00-04:00,RGEN,neutral
1081850.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,RGEN,neutral
1081851.0,44 Stocks Moving In Monday's Mid-Day Session,2019-09-09 12:21:00-04:00,RGEN,neutral
1081852.0,"Mid-Morning Market Update: Markets Mostly Higher; Alcoa To Consolidate Sales, Procurement And Commercial Operations",2019-09-09 10:15:00-04:00,RGEN,neutral
1081853.0,"Stephens & Co. Reinstates Overweight on Repligen, Announces $110 Price Target",2019-08-23 06:47:00-04:00,RGEN,negative
1081854.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,RGEN,positive
1081855.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,RGEN,negative
1081856.0,Stocks That Broke Yearly Highs Thursday Morning,2019-08-01 10:19:00-04:00,RGEN,negative
1081857.0,"Repligen Q2 Adj. EPS $0.31 Beats $0.25 Estimate, Sales $70.7M Beat $63.89M Estimate",2019-08-01 07:37:00-04:00,RGEN,neutral
1081858.0,Stocks That Managed to Breach 52-Week Highs Wednesday Morning,2019-07-31 11:01:00-04:00,RGEN,neutral
1081859.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,RGEN,positive
1081860.0,New Equities that Broke Through 52-Week Highs Monday Morning,2019-07-29 10:13:00-04:00,RGEN,negative
1081861.0,Companies That Achieved 52-Week Highs Friday,2019-07-26 15:37:00-04:00,RGEN,neutral
1081862.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,RGEN,neutral
1081863.0,"Benzinga's Top Upgrades, Downgrades For July 22, 2019",2019-07-22 09:55:00-04:00,RGEN,positive
1081864.0,H.C. Wainwright Upgrades Repligen to Buy,2019-07-22 08:12:00-04:00,RGEN,neutral
1081865.0,Repligen Prices 1.8M Share Common Stock Offering @$87/Share,2019-07-17 03:54:00-04:00,RGEN,positive
1081866.0,Repligen shares are trading lower after the company reported a concurrent $100 million common stock offering and a $250 million convertible senior notes offering.,2019-07-15 16:06:00-04:00,RGEN,neutral
1081867.0,"Repligen Reports Concurrent $100M Common Stock, $250M Convertible Senior Notes Offering",2019-07-15 16:03:00-04:00,RGEN,neutral
1081868.0,"The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO",2019-06-28 07:32:00-04:00,RGEN,negative
1081869.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,RGEN,negative
1081870.0,"The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge",2019-06-20 07:25:00-04:00,RGEN,positive
1081871.0,"The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut",2019-06-19 07:51:00-04:00,RGEN,positive
1081872.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,RGEN,neutral
1081873.0,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",2019-06-05 07:30:00-04:00,RGEN,positive
1081874.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,RGEN,positive
1081875.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,RGEN,neutral
1081876.0,Repligen Raises FY2019 EPS Guidance from $0.81-0.86 to $0.84-0.9; Raises FY2019 Sales Guidance from $218M-225M to $235M-241M,2019-05-09 07:54:00-04:00,RGEN,neutral
1081877.0,"Repligen Q1 EPS $0.28 Beats $0.21 Estimate, Sales $60.6M Beat $52.86M Estimate",2019-05-09 07:51:00-04:00,RGEN,neutral
1081878.0,Repligen shares are trading lower after the company priced a 2.7M share stock offering at $64 per share.,2019-05-01 09:12:00-04:00,RGEN,positive
1081879.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,RGEN,neutral
1081880.0,Repligen Prices 2.7M Share Offering @$64/Share,2019-05-01 03:37:00-04:00,RGEN,positive
1081881.0,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",2019-04-30 08:06:00-04:00,RGEN,positive
1081882.0,Repligen Reports $175M Common Stock Offering,2019-04-29 16:19:00-04:00,RGEN,neutral
1081883.0,48 Biggest Movers From Friday,2019-04-29 05:43:00-04:00,RGEN,neutral
1081884.0,Repligen shares are trading higher after the company entered into an agreement to acquire C Technologies for $240 million; $192 million in cash and $48 million in common stock.,2019-04-26 10:06:00-04:00,RGEN,positive
1081885.0,"Repligen Earlier Issued Preliminary Q1 Results; Sees Q1 Adj. EPS $0.27-$0.28 vs $0.20 Est., Sales $60M-$61M vs $55.78M Est.",2019-04-26 09:53:00-04:00,RGEN,neutral
1081886.0,Repligen Earlier Announced It Will Acquire C Technologies For $240M,2019-04-26 09:43:00-04:00,RGEN,neutral
1081887.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,RGEN,positive
1081888.0,"Repligen Corporation Sees FY19 Adj. EPS $0.81-$0.86 vs $0.85 Est., Sales $218M-$225M vs $217.25M Est.",2019-02-21 07:38:00-05:00,RGEN,neutral
1081889.0,"Repligen Q4 Adj. EPS $0.21, Inline, Sales $51.942M Beat $50.4M Estimate",2019-02-21 07:36:00-05:00,RGEN,neutral
1081890.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,RGEN,positive
1081891.0,Rocket Pharmaceuticals And REGENXBIO Announce New License Agreement For The Treatment Of Danon Disease Using NAV AAV9 Vector; REGENXBIO Grants Rocket Exclusive Worldwide Rights To NAV AAV9 And In Return Will Receive $7M Upfront Payment,2018-11-26 08:37:00-05:00,RGEN,positive
1081892.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,RGEN,neutral
1081893.0,"JP Morgan Maintains Overweight on Repligen, Raises Price Target to $70",2018-11-02 12:51:00-04:00,RGEN,neutral
1081894.0,"The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug",2018-11-02 08:01:00-04:00,RGEN,negative
1081895.0,76 Biggest Movers From Yesterday,2018-11-02 06:12:00-04:00,RGEN,neutral
1081896.0,Repligen shares are up 16.7% after the company beat Q3 earnings estimates and raised FY18 guidance.,2018-11-01 14:22:00-04:00,RGEN,positive
1081897.0,"Repligen Raises FY18 Adj. EPS Guidance From $0.69-$0.73 To $0.71-$0.75 vs $0.71 Estimate, Sales From $185M-$190M To $191M-$194M vs $187.9M Est.",2018-11-01 07:41:00-04:00,RGEN,neutral
1081898.0,"Repligen Corporation Q3 EPS $0.20 Beats $0.18 Estimate, Sales $49.5M Beat $46.74M Estimate",2018-11-01 07:40:00-04:00,RGEN,neutral
1081899.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,RGEN,positive
1081900.0,"Benzinga's Top Upgrades, Downgrades For September 26, 2018",2018-09-26 09:28:00-04:00,RGEN,positive
1081901.0,"H.C. Wainwright Initiates Coverage On Repligen with Neutral Rating, Announces $49 Price Target",2018-09-26 07:11:00-04:00,RGEN,neutral
1081902.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,RGEN,neutral
1081903.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,RGEN,neutral
1081904.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,RGEN,neutral
1081905.0,"The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering",2018-09-07 07:55:00-04:00,RGEN,neutral
1081906.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,RGEN,neutral
1081907.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,RGEN,positive
1081908.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,RGEN,neutral
1081909.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,RGEN,positive
1081910.0,"Repligen Shares Unaffected Following Press Release Highlighting Partnership With Sartorius Stedim Biotech For Introduction Of Next-Gen Perfusion-Enabled Bioreactors, No Terms Disclosed",2018-09-04 11:10:00-04:00,RGEN,neutral
1081911.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,RGEN,neutral
1081912.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,RGEN,neutral
1081913.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,RGEN,neutral
1081914.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,RGEN,neutral
1081915.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,RGEN,positive
1081916.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,RGEN,neutral
1081917.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,RGEN,neutral
1081918.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,RGEN,positive
1081919.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,RGEN,neutral
1081920.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,RGEN,negative
1081921.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,RGEN,neutral
1081922.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,RGEN,negative
1081923.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,RGEN,neutral
1081924.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,RGEN,neutral
1081925.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,RGEN,neutral
1081926.0,"Repligen Sees FY18 Adj. EPS $0.69-$0.73 vs $0.71 Est., Sales $185M-$190M vs $185.35M Est.",2018-08-02 09:30:00-04:00,RGEN,neutral
1081927.0,"Repligen Q2 EPS $0.16 Misses $0.18 Estimate, Sales $47.7M Beat $46.08M Estimate",2018-08-02 09:28:00-04:00,RGEN,negative
1081928.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,RGEN,positive
1081929.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,RGEN,neutral
1081930.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,RGEN,neutral
1081931.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,RGEN,neutral
1081932.0,"Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange",2018-07-06 08:02:00-04:00,RGEN,positive
1081933.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,RGEN,negative
1081934.0,"UPDATE: Repligen Says Co., Navigo Will Co Develop Portfolio Of Next-Gen Ligands Utilizing Navigo's Proprietary Precision Capturing Technology Platform; Repligen To Receive IP Rights, Exclusivity, But No Further Terms Disclosed",2018-06-27 07:34:00-04:00,RGEN,negative
1081935.0,"Repligen Reports Deal With Navigo Proteins For Advancement Of Exclusive Novel Affinity Ligands United In Monoclonal Antibody, Non-Monoclonal Antibody Downstream Purification Processes",2018-06-27 07:33:00-04:00,RGEN,positive
1081936.0,Repligen Raises FY2018 EPS Guidance from $0.68-0.72 to $0.69-0.73 vs $0.70 Est; Raises FY2018 Sales Guidance from $180.0M-186.0M to $182.0M-188.0M vs $183.50M Est,2018-05-08 07:35:00-04:00,RGEN,neutral
1081937.0,"Repligen Q1 EPS $0.17 Beats $0.15 Estimate, Sales $44.83M Beat $43.93M Estimate",2018-05-08 07:34:00-04:00,RGEN,neutral
1081938.0,Repligen Reports Market Launch Of OPUS 80R,2018-03-20 07:31:00-04:00,RGEN,neutral
1081939.0,56 Biggest Movers From Yesterday,2018-02-23 05:17:00-05:00,RGEN,neutral
1081940.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-02-22 12:26:00-05:00,RGEN,neutral
1081941.0,"Repligen Sees FY18 Sales $180-$186M vs $184M Est., EPS $0.68-$0.72 vs $0.72 Est.",2018-02-22 07:39:00-05:00,RGEN,neutral
1081942.0,"Repligen Reports Q4 Adj. EPS $0.20 vs $0.12 Est., Sales $41.6M vs $41.1M Est.",2018-02-22 07:38:00-05:00,RGEN,neutral
1081943.0,"Citigroup Initiates Coverage On Repligen with Buy Rating, Announces $45.00 Price Target",2017-12-08 10:04:00-05:00,RGEN,neutral
1081944.0,"Benzinga's Top Upgrades, Downgrades For December 8, 2017",2017-12-08 09:07:00-05:00,RGEN,positive
1081945.0,"Benzinga's Top Upgrades, Downgrades For December 5, 2017",2017-12-05 09:32:00-05:00,RGEN,positive
1081946.0,"JP Morgan Initiates Coverage On Repligen with Overweight Rating, Announces $42.00 Price Target",2017-12-05 07:14:00-05:00,RGEN,neutral
1081947.0,"CL King Initiates Coverage On Repligen with Buy Rating, Announces $41.00 Price Target",2017-11-13 09:03:00-05:00,RGEN,neutral
1081948.0,Repligen Raises FY17 Adj. EPS Guidance From $0.57-$0.62 To $0.60-$0.63 vs $0.59 Est.,2017-11-09 07:35:00-05:00,RGEN,neutral
1081949.0,Repligen Narrows FY17 Sales Outlook From $138M-$144M To $139M-$142M vs $140.6M Est.,2017-11-09 07:35:00-05:00,RGEN,neutral
1081950.0,"Repligen Reports Q3 Adj. EPS $0.15 vs $0.11 Est., Sales $36.6M vs $35.3M Est.",2017-11-09 07:34:00-05:00,RGEN,neutral
1081951.0,"Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands, Terms Not Disclosed",2017-11-07 07:30:00-05:00,RGEN,positive
1081952.0,Mid-Afternoon Market Update: Ascena Retail Climbs Following Strong Earnings; Axovant Sciences Shares Plunge,2017-09-26 14:31:00-04:00,RGEN,positive
1081953.0,"Jefferies Analyst Earlier Commented On GE Healthcare's Launch Of Protein A Resin: Near-Term Impact On Repligen Will Be Negligible, But Long-Term Impact Will Be Negative",2017-09-26 13:52:00-04:00,RGEN,negative
1081954.0,"Stephens Analyst Earlier Commented On Downside In Repligen Shares: Classifies GE Healthcare's Protein A Resin As 'Niche,' Doesn't See Driving Material Sales For At Least 5 Years; Says Repligen's Sales From GE Will Not Be Impacted, Cites Long-Term Contract",2017-09-26 13:05:00-04:00,RGEN,positive
1081955.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-26 13:04:00-04:00,RGEN,negative
1081956.0,"Repligen Shares Down 15% Tuesday Amid Concern Related To Monday Launch Of GE Healthcare's New Protein A Chromatography Resin, Continued Investment Into Resin",2017-09-26 12:57:00-04:00,RGEN,positive
1081957.0,"Roy T. Eddleman Reports 11% Passive Stake In Repligen Corp as of August 1, 2017 -13G",2017-08-21 06:07:00-04:00,RGEN,positive
1081958.0,"Repligen Reports Q2 Adj. EPS $0.20 vs $0.15 Est., Sales $32.5M vs $31.5M Est.",2017-08-03 07:38:00-04:00,RGEN,neutral
1081959.0,"Repligen Shares Spike ~$0.60 Over Last Min., Now Up 2.1% For Session",2017-08-01 10:20:00-04:00,RGEN,positive
1081960.0,Repligen Prices~2.897M Share Offering @$42.75/Share,2017-06-27 20:05:00-04:00,RGEN,positive
1081961.0,Repligen Announces $15M Offering Common Stock,2017-06-26 17:12:00-04:00,RGEN,neutral
1081962.0,"A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Fed Speakers, Economic Data",2017-06-23 07:21:00-04:00,RGEN,negative
1081963.0,Repligen Reports Deal To Buy Privately-Held Spectrum For ~$359M,2017-06-23 07:00:00-04:00,RGEN,neutral
1081964.0,Repligen Shares Halted News Pending,2017-06-23 06:56:00-04:00,RGEN,positive
1081965.0,"Repligen Reports Q1 Adj. EPS $0.15 vs $0.13 Est., Sales $30.6M vs $29.6M Est.",2017-05-04 07:53:00-04:00,RGEN,neutral
1081966.0,"First Analysis Initiates Coverage On Repligen with Equal-Weight Rating, Announces $40.00 Price Target",2017-04-24 09:39:00-04:00,RGEN,neutral
1081967.0,"PreMarket Prep Recap, March 20: Major Volatility At Friday's Close And Why Disney Is In For A Big Quarter",2017-03-20 10:47:00-04:00,RGEN,neutral
1081968.0,"Repligen Sees FY17 Sales $121-$126M vs. $123M Est., Adj. EPS $0.54-$0.59 vs. $0.55 Est.",2017-02-22 07:31:00-05:00,RGEN,neutral
1081969.0,"Repligen Reports Q4 EPS $0.15 vs. $0.07 Est., Sales $25.59M vs. $24.05M Est.",2017-02-22 07:31:00-05:00,RGEN,neutral
1081970.0,Repligen Acquires TangenX Technology for EUR $37M,2016-12-15 06:58:00-05:00,RGEN,neutral
1081971.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-11-17 06:55:00-05:00,RGEN,neutral
1081972.0,"Repligen Reports Q3 EPS $0.08 vs. Est. $0.08, Rev. $24.7M vs. Est. $24.3M",2016-11-03 07:34:00-04:00,RGEN,neutral
1081973.0,"15 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-09 07:07:00-04:00,RGEN,neutral
1081974.0,"Repligen Sees FY16 Rev. $101-$105M vs. Est. $99.45M, EPS $0.42-$0.48 vs. Est. $0.47",2016-08-04 07:57:00-04:00,RGEN,neutral
1081975.0,"Repligen Reports Q2 Adj. EPS $0.16  vs. Est. $0.13, Rev. $29.2M vs. Est. $24.7M",2016-08-04 07:56:00-04:00,RGEN,neutral
1081976.0,Mid-Afternoon Market Update: Stage Stores Drops On Downbeat Results; Urban Outfitters Shares Surge,2016-05-19 14:30:00-04:00,RGEN,positive
1081977.0,Filing from Repligen Showed Registration for Mixed Securities Shelf Offering,2016-05-18 16:24:00-04:00,RGEN,positive
1081978.0,"Repligen Sees FY16 Sales $98M-$102M vs $96.8M Est., Adj. EPS $0.45-$0.51 vs $0.43 Est.",2016-05-05 07:41:00-04:00,RGEN,neutral
1081979.0,"Repligen Reports Q1 Adj. EPS $0.12 vs $0.10 Est., Sales $25.1M vs $22.5M Est.",2016-05-05 07:40:00-04:00,RGEN,neutral
1081980.0,"Benzinga's M&A Chatter for Monday April 4, 2016",2016-04-04 18:51:00-04:00,RGEN,neutral
1081981.0,"Repligen Acquires Atoll GmbH  For $22.5M, $9.1M Cash And 538K Shares Of Repligen Stock",2016-04-04 07:31:00-04:00,RGEN,positive
1081982.0,"Morgan Stanley Speculates RGEN EPS Impact If Found To Pay Royalties To AMGN; A 5% Royalty Rate Would Negatively Impact EPS ~1-2% Btwn 2017-2020, A 15% Rate Impacts EPS ~3-6%, A 25% Rate Impacts EPS ~5-10%",2016-03-16 08:10:00-04:00,RGEN,negative
1081983.0,"Repligen Sees FY16 Sales $93M-$96M vs $93.6M Est., Net Income $15M-$17M, EBITDA $25M-$27M",2016-02-25 07:33:00-05:00,RGEN,neutral
1081984.0,"Repligen Reports Q4 Adj. EPS $0.07, Inline, Sales $21.4M vs $19.8M Est.",2016-02-25 07:32:00-05:00,RGEN,neutral
1081985.0,Benzinga's Top Initiations,2016-02-22 09:47:00-05:00,RGEN,positive
1081986.0,Craig-Hallum Initiates Coverage on Repligen at Buy,2016-02-22 07:40:00-05:00,RGEN,neutral
1081987.0,Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial,2016-01-21 14:42:00-05:00,RGEN,negative
1081988.0,8 Stocks Moving In Wednesday's After-Hours Session,2016-01-20 16:59:00-05:00,RGEN,neutral
1081989.0,Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance,2016-01-20 14:48:00-05:00,RGEN,negative
1081990.0,Why These Four Stocks Are Moving In Wednesday's After-Hours Session,2015-12-30 16:41:00-05:00,RGEN,neutral
1081991.0,Mid-Afternoon Market Update: Dicks Sporting Goods Slips On Earnings Miss; Airgas Shares Spike Higher,2015-11-17 14:58:00-05:00,RGEN,positive
1081992.0,Repligen Sees FY15 Sales $81M-$83M vs $80.2M Est.,2015-11-05 07:36:00-05:00,RGEN,neutral
1081993.0,"Repligen Reports Q3 EPS $0.08, Inline, Sales $19.8M vs $20.5M Est.",2015-11-05 07:35:00-05:00,RGEN,neutral
1081994.0,Wednesday's After-Hours Movers: 10 Stocks To Watch,2015-09-24 08:10:00-04:00,RGEN,neutral
1081995.0,Repligen Appoints Glenn P. Muir to Board of Directors,2015-09-15 07:31:00-04:00,RGEN,neutral
1081996.0,"Repligen Reports Q2 Product Sales $21.5M vs $20.1M Est., EPS $0.11 vs $0.08 Est.; Sees FY15 Sales $78M-$82M vs $77.5M Est.",2015-08-06 07:41:00-04:00,RGEN,neutral
1081997.0,Regeneron Approval For Praluent To Treat High Cholesterol,2015-07-24 14:18:00-04:00,RGEN,positive
1081998.0,"Repligen Reports Q1 EPS $0.09 vs $0.07 Est., Sales $20.8M vs $18.2M Est.; Raises FY15 Sales Guidance from $72M-$75M to $75M-$78M vs $73.3M Est.",2015-05-07 07:33:00-04:00,RGEN,neutral
1081999.0,"Chardan Capital Initiates Coverage on Regeneron at Buy, Announces $560.00 PT",2015-03-20 10:13:00-04:00,RGEN,neutral
1082000.0,"Repligen Reports Q4 EPS -$0.01 Vs Est +$0.04, Sales $16.4M Vs Est $14.70M",2015-03-13 07:02:00-04:00,RGEN,neutral
1082001.0,Repligen Names Tony Hunt as CEO,2015-01-21 07:03:00-05:00,RGEN,neutral
1082002.0,Repligen Sees FY2015 Sales $69.0M-72.0M vs $70.30M Est,2015-01-08 07:36:00-05:00,RGEN,neutral
1082003.0,Repligen Reports Prelim. FY2014 Sales $63.0M-63.50M vs $61.0M Est,2015-01-08 07:35:00-05:00,RGEN,neutral
1082004.0,Repligen Announces $1M Milestone Payment From Pfizer,2015-01-08 07:34:00-05:00,RGEN,neutral
1082005.0,"CORRECTION: Barclays Initiates Coverage on Regeneron at Equal-weight, Announces $450.00 PT",2015-01-06 08:26:00-05:00,RGEN,neutral
1082006.0,"Repligen Corp CEO Herlihy Sells 51,386 Shares @$23.43/Share -Form 4",2014-11-20 15:37:00-05:00,RGEN,positive
1082007.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,RGEN,neutral
1082008.0,"Repligen Corporation Reports Q3 EPS of $0.04, Inline; Revenue of $15.30M vs $15.60M Est",2014-11-06 07:34:00-05:00,RGEN,neutral
1082009.0,"Regeneron Genetics Center Fully Operational, Announces New Collaborations And Key Appointments ",2014-10-16 08:34:00-04:00,RGEN,neutral
1082010.0,"Option Alert: Repligen Oct $22.5 Call; 2,450 Contract Traded Near Ask @$0.15; Currently $19.11",2014-09-29 09:57:00-04:00,RGEN,positive
1082011.0,Nike Jumps On Strong Results; Powell Industries Shares Slide,2014-09-26 13:04:00-04:00,RGEN,positive
1082012.0,"Option Alert: Repligen Oct $22.5 Call; 2,731 Contracts Traded vs 0 OI; Currently $19.69",2014-08-18 11:13:00-04:00,RGEN,positive
1082013.0,Repligen Corporation Raises FY2014 Sales Guidance from $58.0M-61.0M to $59.0M-62.0M vs $60.10M Est,2014-08-11 07:09:00-04:00,RGEN,neutral
1082014.0,Repligen Corporation Reports Q2 EPS of $0.09 vs $0.06 Est; Revenue of $15.60M vs $14.85M Est,2014-08-11 07:00:00-04:00,RGEN,neutral
1082015.0,"Earnings Scheduled For August 11, 2014",2014-08-11 05:30:00-04:00,RGEN,neutral
1082016.0,Repligen Hires Jon K. Snodgres As CFO,2014-07-15 07:31:00-04:00,RGEN,neutral
1082017.0,2 Biotech Stocks That Crushed On Earnings,2014-07-14 14:35:00-04:00,RGEN,negative
1082018.0,Stocks Hitting 52-Week Highs,2014-06-26 10:15:00-04:00,RGEN,neutral
1082019.0,UPDATE: Repligen Corporation Raises FY2014 Sales Guidance from $52.0M-55.0M to $56.0M-59.0M vs $56.20M Est,2014-06-03 07:04:00-04:00,RGEN,neutral
1082020.0,"Repligen Buys Refine Technology for $20.5Min Cash, 215,285 Shares, Deal Includes Milestone Payment for Up to $8.75M",2014-06-03 07:03:00-04:00,RGEN,positive
1082021.0,Repligen Corporation Sees Q1 Sales $54.0M-57.0M vs $55.22M Est,2014-05-08 07:11:00-04:00,RGEN,neutral
1082022.0,Repligen Corporation Reports Q1 EPS of $0.13 vs $0.09 Est; Revenue of $16.30M vs $15.30M Est,2014-05-08 07:11:00-04:00,RGEN,neutral
1082023.0,Repligen Will Replace Hi-Tech Pharmacal in S&P SmallCap 600,2014-04-15 17:25:00-04:00,RGEN,neutral
1082024.0,Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View,2014-04-15 10:27:00-04:00,RGEN,positive
1082025.0,"Jefferies Initiates Coverage on Repligen Corporation at Buy, Announces $17.00 PT",2014-04-15 07:56:00-04:00,RGEN,neutral
1082026.0,UPDATE: Repligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market,2014-03-26 07:37:00-04:00,RGEN,neutral
1082027.0,Repligen Unveils OPUS(R) Ready-to-Use Chromatography Columns with Largest Capacity on Market,2014-03-26 07:33:00-04:00,RGEN,neutral
1082028.0,Benzinga's Top #PreMarket Losers,2014-03-06 08:16:00-05:00,RGEN,negative
1082029.0,Repligen Corporation Sees FY2014 Sales $54.0M-57.0M,2014-03-06 07:36:00-05:00,RGEN,neutral
1082030.0,Repligen Corporation Reports Q4 EPS of $0.10 vs $0.14 Est; Revenue of $15.40M vs $15.88M Est,2014-03-06 07:30:00-05:00,RGEN,neutral
1082031.0,"BioMarin Confirms Deal with Repligen for HDACI Portfolio, Will Pay $2M Upfront",2014-01-21 07:37:00-05:00,RGEN,negative
1082032.0,"Repligen Announces Asset Buy Deal with BioMarin for HDACI Portfolio, Will Receive Upfront Payment of $2M, Has Potential for Added Milestones of Up to $160M",2014-01-21 07:32:00-05:00,RGEN,positive
1082033.0,Repligen Corporation Reports Q3 EPS of $0.18 vs $0.13 Est; Revenue of $18.80M vs $16.27M Est,2013-11-07 07:30:00-05:00,RGEN,neutral
1082034.0,Repligen Receives First Milestone Payment from Pfizer for Development of Treatment for SMA,2013-09-04 07:13:00-04:00,RGEN,neutral
1082035.0,Stocks Hitting 52-Week Highs,2013-08-01 10:17:00-04:00,RGEN,neutral
1082036.0,Repligen Corporation Raises FY2013 Sales Guidance from $63.0M-65.0M to $65.0M-67.0M,2013-08-01 07:38:00-04:00,RGEN,neutral
1082037.0,Repligen Corporation Reports Q2 EPS of $0.14 vs $0.10 Est; Revenue of $13.0M,2013-08-01 07:31:00-04:00,RGEN,neutral
1082038.0,Amended 13D from Ronald Chez on Repilgen Showing Reduced Stake from 6.09% to 3%,2013-07-23 10:04:00-04:00,RGEN,neutral
1082039.0,Stocks Hitting 52-Week Highs,2013-05-08 09:58:00-04:00,RGEN,neutral
1082040.0,Repligen Corporation Sees FY2013 Sales $63.0M-65.0M vs $56.90M Est,2013-05-02 07:32:00-04:00,RGEN,neutral
1082041.0,Repligen Corporation Reports Q1 EPS of $0.07 vs $0.11 Est; Revenue of $16.50M,2013-05-02 07:31:00-04:00,RGEN,neutral
1082042.0,Stocks Hitting 52-Week Highs,2013-04-08 11:23:00-04:00,RGEN,neutral
1082043.0,Stocks Hitting 52-Week Highs,2013-04-03 11:51:00-04:00,RGEN,neutral
1082044.0,Repligen Sees FY13 Net Income $18-20M,2013-03-07 07:31:00-05:00,RGEN,neutral
1082045.0,"Repligen Corporation Reports Q4 EPS of $(0.30), Down 400% YOY; Revenue of $18.80M",2013-03-07 07:31:00-05:00,RGEN,neutral
1082046.0,"Earnings Scheduled For March 7, 2013",2013-03-07 04:24:00-05:00,RGEN,neutral
1082047.0,Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen,2013-01-03 09:34:00-05:00,RGEN,neutral
1082048.0,Repligen Enters Global Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program ,2013-01-03 07:36:00-05:00,RGEN,positive
1082049.0,Repligen Commericial Chief Resigns,2012-10-26 09:07:00-04:00,RGEN,negative
1082050.0,Robert Baird Raises PT on Repligen from $150 to $175,2012-10-04 08:58:00-04:00,RGEN,neutral
1082051.0,From Earlier: Repligen Names Lieber CFO,2012-09-21 07:10:00-04:00,RGEN,neutral
1082052.0,Repligen Names Jonathan I. Lieber CFO ,2012-09-21 06:32:00-04:00,RGEN,neutral
1082053.0,"Hearing Repligen, Nam Tai Electronics Added to Buy List at Navellier",2012-09-10 11:02:00-04:00,RGEN,neutral
1082054.0,Morning Market Movers,2012-09-10 09:48:00-04:00,RGEN,neutral
1082055.0,Novozymes to Partner With Chemtex to Build US Biofuel Plant,2012-08-22 13:28:00-04:00,RGEN,neutral
1082056.0,"Benzinga's Microcap Movers for Thursday August 2, 2012",2012-08-02 17:30:00-04:00,RGEN,neutral
1082057.0,"Chez Ronald Reports 9.3% Stake in Repligen, Asks Board to Explore Alternatives",2012-07-23 08:31:00-04:00,RGEN,neutral
1082058.0,Repligen Falls After Receiving Complete Response Letter from FDA,2012-06-22 11:04:00-04:00,RGEN,neutral
1082059.0,Benzinga's Top Pre-Market Losers,2012-06-22 08:23:00-04:00,RGEN,negative
1082060.0,"Financial Breakfast: Morning News Summary for June 22, 2012",2012-06-22 07:25:00-04:00,RGEN,neutral
1082061.0,A Peek Into The Market Before The Trading Starts,2012-06-22 07:24:00-04:00,RGEN,neutral
1082062.0,"UPDATE: Repligen: FDA Determined More Clinical Efficacy, Safety Trial Data Will Be Required",2012-06-22 07:02:00-04:00,RGEN,positive
1082063.0,Repligen Receives Complete Response Letter from FDA for RG1068 NDA   ,2012-06-22 07:00:00-04:00,RGEN,neutral
1082065.0,Shareholder Ronald L. Chez Comments on Recent Repligen Developments ,2012-04-30 11:18:00-04:00,RGEN,neutral
1082066.0,Chez Says Spoke to Repligen Chairperson About Proxy Proposal,2012-04-30 11:09:00-04:00,RGEN,neutral
1082067.0,"Benzinga's Microcap Movers for Thursday April 26, 2012",2012-04-26 17:15:00-04:00,RGEN,neutral
1082068.0,Repligen Plummets 40% After FDA Canceled Advisory-Committee Meeting for SecreFlo,2012-04-26 14:45:00-04:00,RGEN,neutral
1082069.0,Repligen Resumes Trading,2012-04-26 10:32:00-04:00,RGEN,neutral
1082070.0,PREVIEW: Repligen to Resume Trading at 10:30am,2012-04-26 10:02:00-04:00,RGEN,neutral
1082071.0,Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting   ,2012-04-26 09:57:00-04:00,RGEN,negative
1082072.0,Repligen Halted; Pending News,2012-04-26 09:20:00-04:00,RGEN,neutral
1082073.0,Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA) ,2012-04-25 10:37:00-04:00,RGEN,positive
1082074.0,Shareholder Says Repligen Corporation Acts to Prevent Proxy Proposal That Would Benefit Investors ,2012-04-11 12:21:00-04:00,RGEN,positive
1082075.0,Repligen Announces FDA Advisory Committee Date for SecreFlo NDA   ,2012-03-23 10:07:00-04:00,RGEN,neutral
1082076.0,Repligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich's Ataxia   ,2012-03-15 14:00:00-04:00,RGEN,neutral
1082077.0,Repligen Announces Submission of Marketing Authorization Application in EU for SecreFlo™ to Improve Pancreatic Imaging in Patients with Pancreatitis   ,2012-03-05 07:00:00-05:00,RGEN,positive
1082078.0,"Financial Breakfast: Morning News Summary for February 21, 2012",2012-02-21 07:29:00-05:00,RGEN,neutral
1082079.0,Repligen Announces FDA Grant of Priority Review for SecreFlo NDA   ,2012-02-21 07:03:00-05:00,RGEN,positive
1082080.0,Repligen Announces Submission of New Drug Application for SecreFlo for Improved Pancreatic Imaging In Patients with Pancreatitis   ,2011-12-21 07:33:00-05:00,RGEN,positive
1082081.0,PREVIEW: Repligen to Resume Trading at 6pm,2011-10-27 17:33:00-04:00,RGEN,neutral
1082082.0,Repligen Acquires Novozymes BioPharma for $22.7M Plus Future Payments,2011-10-27 17:30:00-04:00,RGEN,neutral
1082083.0,Repligen Halted; Pending News,2011-10-27 16:27:00-04:00,RGEN,neutral
1082084.0,Regeneron Up Over 5% After the FDA Announced that Competitor Roche's Avastin Caused Eye Infections,2011-09-02 10:34:00-04:00,RGEN,neutral
1082085.0,Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer  ,2011-07-21 07:21:00-04:00,RGEN,negative
1082086.0,Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors ,2011-07-15 09:20:00-04:00,RGEN,neutral
1082087.0,Wednesday's Put/Call Ratio Leaders,2011-07-13 12:29:00-04:00,RGEN,neutral
1082088.0,Ronald L. Chez Discloses 8.4% Stake in RepliGen  ,2011-07-13 12:26:00-04:00,RGEN,neutral
1082089.0,Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy   ,2011-06-23 07:01:00-04:00,RGEN,neutral
1082090.0,Earnings Scheduled For June 9,2011-06-09 00:35:00-04:00,RGEN,neutral
1082091.0,Repligen Concludes Pre-NDA Meeting with FDA for RG1068   ,2011-06-01 07:02:00-04:00,RGEN,neutral
1082092.0,Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA ,2011-05-19 08:38:00-04:00,RGEN,positive
1082093.0,Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of   Potential Treatment for Spinal Muscular Atrophy,2011-05-19 07:01:00-04:00,RGEN,positive
1082094.0,Trading Resumes: Repligen (RGEN),2011-03-14 11:45:00-04:00,RGEN,neutral
1082095.0,Repligen Reports Positive Phase 3 Clinical Trial Results for RG1068 in Pancreatic Imaging ,2011-03-14 11:13:00-04:00,RGEN,positive
1082096.0,"Trading Halted: Repligen, News Pending (RGEN)",2011-03-14 11:01:00-04:00,RGEN,neutral
1082097.0,"Benzinga's Top Pre-Market NASDAQ Gainers (BSFT, ATRN, RGEN, EMKR)",2011-03-08 08:10:00-05:00,RGEN,positive
1082098.0,Repligen Phase 2b Results for RG2417 for Bipolar Depression Not Demonstrating Significant Improvement  ,2011-03-07 07:36:00-05:00,RGEN,negative
1082099.0,"NASDAQ Stocks Hitting 52-Week Highs (XLNX, CWST, RGEN, PFIN)",2011-01-25 10:45:00-05:00,RGEN,neutral
1082100.0,Regeneron Pharma Bloomberg TV Appearance (RGEN),2011-01-10 14:35:00-05:00,RGEN,neutral
1082101.0,"NASDAQ Stocks Hitting 52-Week Highs (IPCM, SRCL, SNIC, RGEN)",2010-12-29 10:52:00-05:00,RGEN,neutral
1082102.0,Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 ,2010-09-30 07:28:00-04:00,RGEN,neutral
1082103.0,"Benzinga’s Top Pre-Market Gainers (AIXG, CENX, NTAP, SMMX, RGEN)",2010-05-27 08:24:00-04:00,RGEN,positive
1082104.0,Repligen Corp. (RGEN) To Outperform,2009-12-10 15:00:00-05:00,RGEN,neutral
1082105.0,"Benzinga’s Biggest Losers (PIP, ADAT, KR, SVU, AIB) ",2009-12-09 12:26:00-05:00,RGEN,negative
